Bristol Myers Squibb (BMY) EBITDA Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -164.00 |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -611.00 |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 1,581.00 |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -572.00 |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 1,238.00 |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | -194.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,581.00 |
| Mar 31, 2026 | -103.00 |
| Dec 31, 2025 | 1,656.00 |
| Sep 30, 2025 | 815.00 |
| Jun 30, 2025 | 320.00 |
| Mar 31, 2025 | 12,122.00 |
| Dec 31, 2024 | -2,824.00 |
| Sep 30, 2024 | -741.00 |
| Jun 30, 2024 | -718.00 |
| Mar 31, 2024 | -12,357.00 |
| Dec 31, 2023 | -290.00 |
| Sep 30, 2023 | -208.00 |
| Jun 30, 2023 | -265.00 |
| Mar 31, 2023 | 853.00 |
| Dec 31, 2022 | -228.00 |
| Sep 30, 2022 | -13.00 |
| Jun 30, 2022 | 127.00 |
| Mar 31, 2022 | -392.00 |
| Dec 31, 2021 | 11,656.00 |
| Sep 30, 2021 | 117.00 |